Skip to content
S1350Senate2023-2024 SessionSame asA3693

Count Coupons Toward Drug Costs

Official title

“Relates to brand-name drugs with and without an AB generic equivalent”

Sponsor Gustavo RiveraSD-33Affects Finance
Status
Signed by Governor
Impact
7/10
Significant
Outcome
Signed into law

Bill progress

Signed into law

What's happening

This bill limits when insurers must count third-party prescription drug payments toward out-of-pocket maximums, applying only to certain drugs.

Why it matters

  1. Narrows scope of insurer requirements. By limiting when insurers must count third-party payments (like copay assistance) toward out-of-pocket maximums to only certain drugs, the bill reduces the range of drugs for which patient financial help “counts” for insurance cost-sharing protections. This could lead to higher out-of-pocket costs for patients using drugs outside the specified categories.

  2. Defines eligible drug categories. Insurers must count third-party payments only for (A) brand-name drugs without an AB-rated generic equivalent, (B) brand-name drugs with an AB-rated generic equivalent only if the patient gets prior authorization or wins an appeal, or (C) any generic drug the insurer covers. This restricts patient benefit to scenarios where less expensive options are not available or when the insurer has approved brand-name use.

  3. Potential impact on patient access and drug choice. Patients using brand-name drugs where a generic is available (but without insurer authorization) will likely find that third-party assistance does not help them reach their deductible or out-of-pocket maximum, potentially discouraging use of brand-name drugs unless medically necessary and insurer-approved.

  4. Delays implementation timeline. The act changes the effective date for these changes from January to July, giving insurers, pharmacies, and patients additional time to adjust to the new rules and coverage calculations.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Count Coupons Toward Drug Costs

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Gustavo Rivera

Senator · Senate District 33

Chair, Health

No co-sponsors yet.

History

  1. Signed chap.117
  2. Delivered to governor
  3. Returned to senate
  4. Passed assembly
  5. Ordered to third reading cal.40
  6. Substituted for A3693
  7. Referred to insurance
  8. Delivered to assembly
  9. Passed senateVote 63–0
  10. Ordered to third reading cal.118
  11. Referred to rules

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A3693Assembly

Count Copay Assistance for Drugs

Assembly Floor Calendar · Sponsor David Weprin

Impact 7 · Significant0% to pass

Full text

3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

1350

2023-2024 Regular Sessions

IN SENATE

January 11, 2023

Introduced by Sen. RIVERA -- read twice and ordered printed, and when printed to be committed to the Committee on Rules

AN ACT to amend the insurance law, in relation to calculating an insured individual's overall contribution to any out-of-pocket maximum or any cost-sharing requirement; and to amend a chapter of the laws of 2022 amending the insurance law relating to calculating an insured individual's overall contribution to any out-of-pocket maximum or any costsharing requirement, as proposed in legislative bills numbers S.

5299-A and A. 1741-A, in relation to the effectiveness thereof

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Paragraph 37 of subsection (i) of section 3216 of the insurance law, as added by a chapter of the laws of 2022 amending the insurance law relating to calculating an insured individual's overall contribution to any out-of-pocket maximum or any cost-sharing requirement, as proposed in legislative bills numbers S. 5299-A and A. 1741-A, is amended to read as follows:

(37) Any policy that provides coverage for prescription drugs shall apply any third-party payments, financial assistance, discount, voucher or other price reduction instrument for out-of-pocket expenses made on behalf of an insured individual for the cost of a prescription [drugs] drug to the insured's deductible, copayment, coinsurance, out-of-pocket maximum, or any other cost-sharing requirement when calculating such insured individual's overall contribution to any out-of-pocket maximum or any cost-sharing requirement. If under federal law, application of this requirement would result in health savings account ineligibility under 26 USC 223, this requirement shall apply for health savings account-qualified high deductible health plans with respect to the deductible of such a plan after the enrollee has satisfied the minimum deductible under 26 USC 223, except for with respect to items or services that are preventive care pursuant to 26 USC 223(c)(2)(C), in

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD04217-01-3

which case the requirements of this paragraph shall apply regardless of whether the minimum deductible under 26 USC 223 has been satisfied. This paragraph only applies to a prescription drug that is either (A) a brand-name drug without an AB rated generic equivalent, as determined by the United States Food and Drug Administration; or (B) a brand-name drug with an AB rated generic equivalent, as determined by the United States Food and Drug Administration, and the insured has access to the brandname drug through prior authorization by the insurer or through the insurer's appeal process, including any step-therapy process; or (C) a generic drug the insurer will cover, with or without prior authorization or an appeal process.

§ 2. Paragraph 21 of subsection (l) of section 3221 of the insurance law, as added by a chapter of the laws of 2022 amending the insurance law relating to calculating an insured individual's overall contribution to any out-of-pocket maximum or any cost-sharing requirement, as proposed in legislative bills numbers S. 5299-A and A. 1741-A, is amended to read as follows:

(21) Every group or blanket policy delivered or issued for delivery in this state that provides coverage for a prescription [drugs] drug shall apply any third-party payments, financial assistance, discount, voucher or other price reduction instrument for out-of-pocket expenses made on behalf of an insured individual for the cost of prescription drugs to the insured's deductible, copayment, coinsurance, out-of-pocket maximum, or any other cost-sharing requirement when calculating such insured individual's overall contribution to any out-of-pocket maximum or any cost-sharing requirement. If under federal law, application of this requirement would result in health savings account ineligibility under 26 USC 223, this requirement shall apply for health savings account-qualified high deductible health plans with respect to the deductible of such a plan after the enrollee has satisfied the minimum deductible under 26 USC 223, except for with respect to items or services that are preventive care pursuant to 26 USC 223(c)(2)(C), in which case the requirements of this paragraph shall apply regardless of whether the minimum deductible under 26 USC 223 has been satisfied. This paragraph only applies to a prescription drug that is either (A) a brand-name drug without an AB rated generic equivalent, as determined by the United States Food and Drug Administration; or (B) a brand-name drug with an AB rated generic equivalent, as determined by the United States Food and Drug Administration, and the insured has access to the brand-name drug through prior authorization by the insurer or through the insurer's appeal process, including any step-therapy process; or (C) a generic drug the insurer will cover, with or without prior authorization or an appeal process.

§ 3. Subsection (tt) of section 4303 of the insurance law, as added by a chapter of the laws of 2022 amending the insurance law relating to calculating an insured individual's overall contribution to any out-ofpocket maximum or any cost-sharing requirement, as proposed in legislative bills numbers S. 5299-A and A. 1741-A, is amended to read as follows:

(tt) Every contract issued by a medical expense indemnity corporation, hospital service corporation, or health service corporation that provides coverage for a prescription [drugs] drug shall apply any thirdparty payments, financial assistance, discount, voucher or other price reduction instrument for out-of-pocket expenses made on behalf of an insured individual for the cost of prescription drugs to the insured's deductible, copayment, coinsurance, out-of-pocket maximum, or any other cost-sharing requirement when calculating such insured individual's overall contribution to any out-of-pocket maximum or any cost-sharing requirement. If under federal law, application of this requirement would result in health savings account ineligibility under 26 USC 223, this requirement shall apply for health savings account-qualified high deductible health plans with respect to the deductible of such a plan after the enrollee has satisfied the minimum deductible under 26 USC 223, except for with respect to items or services that are preventive care pursuant to 26 USC 223(c)(2)(C), in which case the requirements of this paragraph shall apply regardless of whether the minimum deductible under 26 USC 223 has been satisfied. This subsection only applies to a prescription drug that is either (A) a brand-name drug without an AB rated generic equivalent, as determined by the United States Food and Drug Administration; or (B) a brand-name drug with an AB rated generic equivalent, as determined by the United States Food and Drug Administration, and the insured has access to the brand-name drug through prior authorization by the insurer or through the insurer's appeal process, including any step-therapy process; or (C) a generic drug the insurer will cover, with or without prior authorization or an appeal process.

§ 4. Section 4 of a chapter of the laws of 2022 amending the insurance law relating to calculating an insured individual's overall contribution to any out-of-pocket maximum or any cost-sharing requirement, as proposed in legislative bills numbers S. 5299-A and A. 1741-A, is amended to read as follows:

§ 4. This act shall take effect on the first of [January] July next succeeding the date on which it shall have become a law and shall apply to all policies and contracts issued, renewed, modified, altered or amended on or after such date.

§ 5. This act shall take effect immediately; provided, however, that sections one, two and three of this act shall take effect on the same date and in the same manner as a chapter of the laws of 2022 amending the insurance law relating to calculating an insured individual's overall contribution to any out-of-pocket maximum or any cost-sharing requirement, as proposed in legislative bills numbers S. 5299-A and A. 1741-A, takes effect.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the insurance law, in relation to calculating an insured individual's overall contribution to any out-of-pocket maximum or any cost-sharing requirement; and to amend a chapter of the laws of 2022 amending the insurance law relating to calculating an insured individ- ual's overall contribution to any out-of-pocket maximum or any cost- sharing requirement, as proposed in legislative bills numbers S. 5299-A and A. 1741-A, in relation to the effectiveness thereof

Purpose

This is a chapter amendment that makes changes to provisions of L.2022, c.736, to clarify provisions relating to calculating an insured individ- ual's overall contribution to any out-of-pocket maximum or any cost- sharing requirement

Summary of provisions

The underlying chapter requires health plans and pharmacy benefit manag- ers to count manufacturers' discounts towards a person's cost-sharing maximum calculation. The changes limit the application of the copay accumulator to brand-name drugs without a generic equivalent; or with a generic equivalent that are accessed through prior authorization or appeals; and all generic drugs.

Existing law

None

Justification

This legislation is a negotiated change to the underlying chapter.

Legislative history

Chapter amendment to Chapter 736 of the Laws of 2022. S. 5299-A and A.1741-A both passed the Senate and Assembly in May 2022.

Fiscal implications

None

Effective date

This act shall take effect immediately; provided, however, that sections one, two and three of this act shall take effect on the same date and in the same manner as a chapter of the laws of 2022 amending the insurance law relating to calculating an insured individual's overall contribution to any out-of-pocket maximum or any cost-sharing requirement, as proposed in legislative bills numbers S. 5299-A and

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.